文献速递中枢神经肿瘤放疗放疗物理与技术

脑转移瘤术前立体定向放射外科治疗的回顾性剂量-体积研究

Pre-operative stereotactic radiosurgery for cerebral metastatic disease: A retrospective dose-volume study.
PubMed 文献 · Radiother Oncol · 2022-07-26

本研究回顾性分析2家学术机构47例脑转移瘤患者,比较术后立体定向放射外科(SRS)实际计划与假设的术前SRS计划的剂量学差异。结果显示术前SRS的中位处方剂量(16 Gy vs 24 Gy)、适形指数和梯度指数更优,正常脑组织接受10 Gy、12 Gy、14 Gy的体积均显著低于术后SRS(均p<0.0001)。作者认为新辅助SRS可降低处方剂量并减少正常脑组织受照,这些发现可能支持其用于脑转移瘤治疗。

要点

  • 术前SRS中位处方剂量16 Gy,低于术后SRS的24 Gy(p<0.0001)。
  • 术前SRS适形指数1.23 vs 术后1.29(p=0.0098),梯度指数2.72 vs 2.94(p=0.0004),均更优。
  • 正常脑组织接受10 Gy、12 Gy、14 Gy的体积术前均显著低于术后(均p<0.0001)。

核心结论

  • 新辅助SRS与更低的处方剂量、更好的适形性和更少的正常脑组织受照相关。
  • 作者认为这些发现可能支持新辅助SRS用于脑转移瘤的治疗。

研究设计与样本

  • 回顾性分析2家学术机构47例脑转移瘤,患者接受手术切除后行SRS至手术床。
  • 术后体积和剂量学数据来自记录或实际计划重建,术前数据来自假设的放疗计划,采用Wilcoxon符号秩检验比较。

主要发现

  • 术后计划肿瘤体积中位12.28 cc(IQR 6.54–18.69)vs 术前10.20 cc(IQR 4.53–21.70),p=0.4150。
  • 中位处方剂量术前16 Gy vs 术后24 Gy,p<0.0001。
  • 适形指数术前1.23(IQR 1.20–1.29)vs 术后1.29(IQR 1.23–1.39),p=0.0098。
  • 梯度指数术前2.72(IQR 2.59–2.98)vs 术后2.94(IQR 2.69–3.47),p=0.0004。
  • 正常脑组织接受10 Gy体积术前12.97 cc(IQR 6.78–25.54)vs 术后32.13 cc(IQR 19.42–48.40),12 Gy术前9.31 cc(IQR 4.56–17.43)vs 术后23.80 cc(IQR 14.74–36.56),14 Gy术前5.62 cc(IQR 3.23–11.61)vs 术后17.47 cc(IQR 9.00–28.31),均p<0.0001,均偏向术前SRS。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stereotactic radiosurgery (SRS) after maximal safe resection is an accepted treatment strategy for patients with cerebral metastatic disease. Despite its high conformality profile, the incidence of radionecrosis (RN) remains high. SRS delivered pre-operatively could be associated with a reduced incidence of RN. We sought to evaluate whether neoadjuvant SRS could reduce radiotherapy doses in a cohort of patients treated with post-operative SRS. METHODS: A cohort of 47 brain metastases (BM) treated at 2 academic institutions was retrospectively analyzed. Subjects underwent surgical extirpation of BMs and subsequent SRS to surgical bed. Post-operative volumetric and dosimetric data was collected from records or recreations of delivered plans; pre-operative data were derived from hypothetical radiotherapy courses and compared using Wilcoxon signed-rank tests. RESULTS: Higher planned tumor volume post-operatively (median[IQR] 12.28 [6.54, 18.69]cc vs 10.20 [4.53, 21.70]cc respectively, p = 0.4150) was observed. The median prescribed radiotherapy dose (DRx) was 16 Gy pre-operatively and 24 Gy post-operatively (p < 0.0001). Further investigations revealed improved pre-operative conformity index (1.23[1.20, 1.29] vs 1.29[1.23, 1.39], p = 0.0098) and gradient index (2.72[2.59, 2.98] vs 2.94[2.69, 3.47], p = 0.0004). A significant difference was found in normal brain tissue exposed to 10 Gy (12.97[6.78, 25.54]cc vs 32.13[19.42, 48.40]cc, p < 0.0001), 12 Gy (9.31[4.56, 17.43]cc vs 23.80[14.74, 36.56]cc, p < 0.0001), and 14 Gy (5.62[3.23, 11.61]cc vs 17.47[9.00, 28.31]cc, p < 0.0001), favoring pre-operative SRS. CONCLUSIONS: Neoadjuvant SRS is associated reduced DRx, better conformality profile and decreased radiation to normal tissue. These findings could support the use of neoadjuvant SRS for the treatment of BMs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Bugarini A, Meekins E, Salazar J, et al. Pre-operative stereotactic radiosurgery for cerebral metastatic disease: A retrospective dose-volume study. Radiother Oncol. 2022. PMID: 35905780. doi:10.1016/j.radonc.2022.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。